v3.26.1
Segment Reporting (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
numberOfSegments
Jun. 30, 2025
USD ($)
Segment Reporting [Abstract]            
Number of reportable segments | numberOfSegments         1  
Segment Reporting Information [Line Items]            
Revenues $ 1,014   $ 10,739   $ 180,140 $ 12,503
General and administrative 3,867   3,328   9,756 9,160
Restructuring costs 0   165   0 12,538
Net Income (Loss) (5,143) $ 169,695 2,523 $ (24,526) 164,552 (22,003)
Adjustments and reconciling items 0   0   0 0
Reportable Segment            
Segment Reporting Information [Line Items]            
Revenues 1,014   10,739   180,140 12,503
Imdusiran IM-PROVE I, II & III clinical trials expense 326   1,618   1,217 3,789
AB-101-001 Phase 1a/1b clinical trial expense 183   1,738   709 3,637
Other early research and development programs expense 2,389   2,142   5,092 7,031
General and administrative 3,867   3,328   9,756 9,160
Restructuring costs 0   165   0 12,538
Other segment expense 234   267   471 590
Interest income 842   1,042   1,657 2,239
Net Income (Loss) $ (5,143)   $ 2,523   $ 164,552 $ (22,003)
Consolidated net loss (5,143)   2,523   164,552 (22,003)